Decreased amyloid-β and increased neuronal hyperactivity by immunotherapy in Alzheimer's models

被引：0
|
作者：
Marc Aurel Busche
Christine Grienberger
Aylin D Keskin
Beomjong Song
Ulf Neumann
Matthias Staufenbiel
Hans Förstl
Arthur Konnerth
机构：
[1] Institute of Neuroscience,Department of Psychiatry and Psychotherapy
[2] Technische Universität München,Department of Cellular Neurology
[3] Technische Universität München,undefined
[4] Munich Cluster for Systems Neurology (SyNergy),undefined
[5] Janelia Farm Research Campus,undefined
[6] Howard Hughes Medical Institute,undefined
[7] Novartis Institute for BioMedical Research,undefined
[8] Hertie Institute for Clinical Brain Research,undefined
[9] University of Tübingen,undefined
来源：
Nature Neuroscience | 2015年 / 18卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Immunotherapy with antibodies targeting the amyloid-β peptide has yet to show any cognitive benefit in Alzheimer's disease patients in clinical trials. In vivo two-photon imaging in mouse models of Alzheimer's disease now reveals that these antibodies do not alleviate neuronal dysfunction and can even worsen it.
引用
收藏
页码：1725 / 1727
页数：2
相关论文
共 50 条
  • [1] Decreased amyloid-β and increased neuronal hyperactivity by immunotherapy in Alzheimer's models
    Busche, Marc Aurel
    Grienberger, Christine
    Keskin, Aylin D.
    Song, Beomjong
    Neumann, Ulf
    Staufenbiel, Matthias
    Foerstl, Hans
    Konnerth, Arthur
    NATURE NEUROSCIENCE, 2015, 18 (12) : 1725 - 1727
  • [2] Amyloid-β Immunotherapy for Alzheimer's Disease
    Fu, H. J.
    Liu, B.
    Frost, J. L.
    Lemere, C. A.
    CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2010, 9 (02) : 197 - 206
  • [3] Amyloid-β-directed immunotherapy for Alzheimer's disease
    Lannfelt, L.
    Relkin, N. R.
    Siemers, E. R.
    JOURNAL OF INTERNAL MEDICINE, 2014, 275 (03) : 284 - 295
  • [4] Biomarkers in Amyloid-β Immunotherapy Trials in Alzheimer's Disease
    Blennow, Kaj
    Hampel, Harald
    Zetterberg, Henrik
    NEUROPSYCHOPHARMACOLOGY, 2014, 39 (01) : 189 - 201
  • [5] Amyloid-β immunotherapy for Alzheimer's disease:: the end of the beginning
    Schenk, D
    NATURE REVIEWS NEUROSCIENCE, 2002, 3 (10) : 824 - 828
  • [6] Biomarkers in Amyloid-β Immunotherapy Trials in Alzheimer’s Disease
    Kaj Blennow
    Harald Hampel
    Henrik Zetterberg
    Neuropsychopharmacology, 2014, 39 : 189 - 201
  • [7] Amyloid-β immunotherapy for Alzheimer's disease: the end of the beginning
    Dale Schenk
    Nature Reviews Neuroscience, 2002, 3 : 824 - 828
  • [8] Glutamate perpetuates amyloid-β-dependent neuronal hyperactivity
    Wood, Heather
    NATURE REVIEWS NEUROLOGY, 2019, 15 (10) : 558 - 559
  • [9] Glutamate perpetuates amyloid-β-dependent neuronal hyperactivity
    Heather Wood
    Nature Reviews Neurology, 2019, 15 : 558 - 559
  • [10] Immunotherapy for Alzheimer's disease:: attacking amyloid-β from the inside
    Arbel, Michal
    Solomon, Beka
    TRENDS IN IMMUNOLOGY, 2007, 28 (12) : 511 - 513
12345